Human Immunodeficiency Virus 1 Drug Resistance by Next Generation Sequencing
Also known as: HIV1 NGS
Use
This test provides antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (NRTI, NNRTI), and integrase inhibitors (INT). It is designed for patients with a viral load greater than 500 copies/mL. The test predicts HIV-1 resistance by sequencing the protease, integrase, and reverse transcriptase genes of the viral genome. Using next generation sequencing, it detects mutations that confer drug resistance, helping guide treatment decisions in conjunction with clinical presentation and other laboratory markers.
Special Instructions
Not provided.
Limitations
This test's sensitivity is sensitive to viral load, requiring over 500 copies/mL for successful detection. While it detects down to 10 percent minority populations, small indels may be missed. Drug resistance is interpreted via the Stanford hivdb database, with potential variation in resistance levels. Not all sequences may achieve full coverage (i.e., may be listed as 'Not Determined'). This method faces inherent challenges, such as difficulty in capturing rapidly evolving viral genomes or when dealing with viral quasispecies, and variations in viral genetic polymorphisms might affect resistance predictions.
New York Approved
Methodology
NGS (Massively Parallel Sequencing)
Biomarkers
No genes
Gene
LOINC Codes
- 80689-3 - HIV 1 RNA RT + PR + IN Mut Det Plas Seq
- 11502-2 - Laboratory report
Result Turnaround Time
4-10 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3.0 mL
Minimum Volume
2.5 mL
Container
ARUP standard transport tube
Collection Instructions
Separate plasma from cells within 24 hours.
Causes for Rejection
Serum and heparinized specimens are unacceptable.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 72 hours |
| Frozen | 3 months |
Other tests from different labs that may be relevant